Sanofi-aventis Expands its Early-Stage Pipeline

By Heather Cartwright

Pharma Deals Review: Vol 2010 Issue 7 (Table of Contents)

Published: 21 Sep-2010

DOI: 10.3833/pdr.v2010.i7.1377     ISSN: 1756-7874

Section: Licensing



Sanofi-aventis has acquired rights to Ascenta Therapeutics’ early-stage oral cancer drug candidates while its Sanofi Pasteur vaccine division has signed a partnership with the French biotech Vivalis for the development of human monoclonal antibodies against various infectious diseases...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details